Drug Profile
CP 640922
Alternative Names: CP-640922Latest Information Update: 17 Aug 2007
Price :
$50
*
At a glance
- Originator Pfizer
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Skin disorders
Most Recent Events
- 31 Jul 2007 Discontinued - Phase-II for Skin disorders in USA (unspecified route)
- 20 Dec 2006 Phase-II clinical trials in Skin disorders in USA (unspecified route)